Clinical Trial Update: Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy [Phase 2]

View source ↗

Summary

A Phase 2 trial of subcutaneously administered peginesatide in anemic cancer patients receiving chemotherapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Chemotherapy-induced Anemia

Drugs mentioned

• OMontys (peginesatide)

Snippet

Sponsor: Affymax | Conditions: Chemotherapy Induced Anemia, Cancer | Phase 2 | Status: COMPLETED